EXCLI Journal https://www.excli.de/index.php/excli <center><img class="img-responsive" src="/public/site/images/lindemann/Lucida_logo_neu_geschrieben.PNG" alt="EXCLI Journal Logo"></center> <p>EXCLI Journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.</p> <div class="toggleBox"><input id="toggleContent" name="toggleContent" type="checkbox"> <label class="open" for="toggleContent">More...</label> <label class="close" for="toggleContent">Less...</label> <div> <p><strong>EXCLI Journal </strong>(eISSN 1611-2156)&nbsp;is particularly keen to keep a broad view of science and technology, and therefore welcomes papers which bridge disciplines and may not suit the narrow specialism of other journals. Although the general emphasis is on biological sciences, studies from the following fields are explicitly encouraged:</p> <p>Immunology, toxicology, ergonomics, neurosciences, psychology, occupational medicine, clinical and preclinical studies, drug development, pharmacology, environmental health, chemistry including analytical chemistry, biochemistry, cell biology, genetics, forensic medicine, oncology and cancer research, proteomics, systems biology, hepatology and gastroenterology, aging research, psychiatric research, behavioral sciences.</p> </div> </div> en-US <p>Authors who publish in this journal agree to the following terms:</p> <ul> <li>The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener">CC BY 4.0</a>. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.</li> <li>The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.</li> <li>Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.</li> <li>The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).</li> </ul> excli@ifado.de (EXCLI Journal) excli@ifado.de (Webmaster) Mon, 04 Jan 2021 08:22:24 +0100 OJS http://blogs.law.harvard.edu/tech/rss 60 Prognostic Markers in CKD Patients stratified by co-morbid conditions and on Dialysis Therapy https://www.excli.de/index.php/excli/article/view/4466 <p><strong>Objective:&nbsp;</strong>This study aimed to investigate patients with chronic renal insufficiency and co-morbidities undergoing dialysis for genomic damage measured using the comet assay and to determine prognostic factors which may be useful for interventional strategies as a part of CKD support, care and management.</p> <p><strong>Methods:&nbsp;</strong>In this case-control study, patients undergoing twice weekly hemodialysis sessions comprised Diabetic Nephropathy (DN), Diabetic Nephropathy and Hypertension (DNH), Nephropathy and Hypertension (NH), Nephropathy, Hypertension and Miscellaneous conditions (NHM) and Nephropathy and Miscellaneous conditions (NM) sub-groups.&nbsp; DNA damage was measured using the alkaline comet assay in peripheral blood cells and demographic, clinical and medicinal details were recorded.</p> <p><strong>Results:&nbsp;T</strong>he patients (52.17±10.30y) had significantly (p&lt;0.001) elevated genetic damage varying from 1.68-3.91folds across the six damage parameters compared to controls (51.29±10.27y). Of these, per cent tail DNA, Damage Index (DI) and mean DNA migration length showed independent interaction in patients. Significance within sub-groups related to DI (DNH&gt; DN&gt;NM), per cent tail DNA (DNH&gt;NM) and mean DNA migration length (DNH&gt;NM) with maximal DNA damage in patients with diabetes and/or hypertension as co-morbidities.&nbsp;</p> <p>On MDR analysis, a machine-learning tool, the best model with maximal testing accuracy (95.24%) and 10/10 CV consistency comprised per cent tail DNA, damage index and mean DNA migration length and showed independent interaction as prognostic markers. On PCA, clusters of factors were identified in disease- progression/prognosis as principal component one (PC1:55.66/78.87% CV) comprised DI, mean DNA migration length, per cent tail DNA, urea, creatinine and haemoglobin levels, time-on-medication, time-on-dialysis and medication status.</p> <p><strong>Conclusion:&nbsp;</strong>The determinants (primarily genetic damage, creatinine levels, time-on-medication, time-on- dialysis) which have emerged on MDR analysis and PCA in CKD patients on dialysis can be regarded as prognostic markers of clinical significance in the local scenario where extracorporeal dialysis (hemodialysis) using the diffusive technique (acetate and bicarbonate dialysis removing low molecular weight solutes) is the only option available to most patients. Given the correlation of DNA damage and mortality risk in CKD patients reported in literature, the significantly increased DNA damage observed across patient sub-groups may be considered prognostic through periodic bio-monitoring and longitudinal inferences in further studies.</p> Gurleen Tung, Gursatej Gandhi Copyright (c) https://www.excli.de/index.php/excli/article/view/4466 Effects of curcuminoid–piperine combination on oxidative stress and antioxidant capacity in women with premenstrual syndrome and dysmenorrhea: A post-hoc analysis of a randomized clinical study https://www.excli.de/index.php/excli/article/view/4465 <p>There is evidence supporting a role of oxidative stress in the pathoetiology of menstrual associated complications. Curcuminoids, are polyphenolic natural compounds that have potentially important functional activities, including antioxidant properties. This randomized, triple-blind, placebo-controlled trial was performed to investigate the effects of a curcumin on oxidative stress and antioxidant capacity in women with premenstrual syndrome (PMS) and dysmenorrhea. Eighty women with both PMS and dysmenorrhea were randomized to receive either curcuminoids (500mg + 5mg piperine) or placebo daily, for a period from 7 days before until 3 days after initiation of menstrual bleeding for 3 successive menstrual cycles<strong>. </strong>Anthropometrical, and biochemical characteristics, as well as dietary intake of participants were assessed at baseline and post intervention. The total antioxidant capacity and free radical scavenging activity of serum and urine were quantified using the ferric reducing/antioxidant power (FRAP) and α, α-diphenyl-β-picrylhydrazyl (DPPH) methods, respectively. Malondialdehyde (MDA), as a marker of oxidative stress, was also measured using a method based on the formation of thiobarbituric acid reactive substances. At baseline, no significant differences were found between the placebo and curcumin groups, with respect to the age, dietary intake and biochemical/anthropometric indices (p&gt;0.05). Curcumin significantly promoted the free radical scavenging activity of serum compared to the placebo (P=0.031). However, no significant changes were detected in serum and urinary levels of FRAP, DPPH and MDA between the groups (p&gt;0.5). Curcumin improves radical scavenging activity and antioxidant potential in women with PMS and dysmenorrhea. Studies with higher doses and duration of curcumin are needed to verify our findings.</p> Asghar Zarban, Samira Karbasi, Saman Seyedabadi, Samira Mozaffari, Gordon A. Ferns, Afsane Bahrami Copyright (c) https://www.excli.de/index.php/excli/article/view/4465 Long noncoding RNA LUCAT1 promotes malignancy of bladder cancer through epithelial-mesenchymal transition https://www.excli.de/index.php/excli/article/view/4457 <p>Lung cancer associated transcript 1(LUCAT1) has been suggested to play a vital regulatory role in several cancers. However, the biological function of LUCAT1 in bladder cancer was still unknown. In this study, we observed that the expression of LUCAT1 was significantly increased in bladder cancer tissues and cell lines. Functional experiments revealed that knockdown of LUCAT1 inhibited bladder cancer cell proliferation, migration and invasion. In contrast, up-regulated LUCAT1 facilitated cell proliferation, migration and invasion in bladder cancer cells. The malignant phenotype of LUCAT1 was validated <em>in vivo</em>. Furthermore, the mRNA expression profiles after LUCAT1 knockdown was analyzed by RNA-sequencing. Moreover, both the GO (Gene Ontology) analysis and Pathways results showed epithelial-mesenchymal transition (EMT) may participate the malignant process. Subsequently, we confirmed that the expression of EMT related genes including: Slug, N-cadherin and vimentin were significantly increased in the overexpression of LUCAT1 group to the control. By combining our sequencing data with predictions, E2F1 and DEPCA1 may be involved in malignant processes. These results indicated that LUCAT1 may promote bladder cancer development through EMT via interact with E2F1 and DEPCA1.</p> Yuepeng Cao, Shiye Jiang, Xuhong Wu, Zhen Lu, Jiawei Hu, Chenshuai Si, Peng Shao, Chuanfei Zhan, Chao Wang, Xin Zhou, Liu Yang Copyright (c) https://www.excli.de/index.php/excli/article/view/4457